Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms ROBIN
- 07 Jun 2017 Biomarkers information updated
- 08 Oct 2010 Top-line results reported in a Targacept media release.
- 10 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.